Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Hydreight to distribute HSC's at-home STI testing kits

NURS · Price

Executive Summary

  • Hydreight Technologies Inc. has entered the at-home sexually transmitted infection (STI) prescreening market through an exclusive distribution agreement with Health Screen Collective (HSC).
  • The company has secured approximately 50,000 pre-orders for HSC's at-home STI prescreen testing kits, with deliveries scheduled to begin in early 2026.
  • The agreement positions Hydreight to leverage its existing mobile clinic and digital health infrastructure to integrate prescreening results with licensed medical review, confirmatory testing, and treatment coordination.

Key Details

  • Agreement Structure: Exclusive distribution agreement granting Hydreight rights to distribute HSC's at-home STI prescreen testing kits across its national platform.
  • Commercial Traction: Approximately 50,000 pre-orders secured from enterprise partners, health care operators, and distribution channels.
  • Timeline: Deliveries of testing kits are expected to begin in early 2026.
  • Product Technology: HSC kits utilize validated lateral-flow immunoassay technology to deliver results in minutes rather than days.
  • Tested Pathogens: The kits provide prescreening for:
    • Chlamydia trachomatis
    • Neisseria gonorrhoeae
    • Trichomonas vaginalis
    • Mycoplasma genitalium
    • Candida albicans
    • Gardnerella vaginalis
  • Performance Metrics: Product validation data indicates high levels of sensitivity, specificity, and overall accuracy, with performance characteristics comparable to commonly used laboratory-based screening methods for initial detection.
  • Strategic Integration: The prescreening tool is integrated into Hydreight’s platform to facilitate a seamless workflow from prescreening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination.
  • Platform Leverage: Hydreight views this offering as a driver for repeat engagement, downstream clinical services, pharmacy fulfillment, and long-term platform utilization, rather than a standalone product.

Notable Quotes

  • "This category highlights exactly why our platform exists," said Shane Madden, chief executive officer of Hydreight. "When you combine fast, at-home screening with licensed providers and national fulfilment, you remove friction from a category that desperately needs it. That's where real health care transformation happens."
Read the original news release →

More from Hydreight Technologies Inc